# A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet

> **NCT00566267** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 58 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** simvastatin 20 mg/ezetimibe

## Key facts

- **NCT ID:** NCT00566267
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2007-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566267, "A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00566267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*